Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02278367 · ClinicalTrials.gov registry record · Phase 2
Clinical Evaluation of Flortaucipir F 18
A Phase 2 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 179
- Enrollment target
NCT02278367 is a Phase 2 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 179 participants.
The verdict
NCT02278367, a Phase 2 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 179 participants
- Enrollment target
Study Summary
This study is designed to expand the database of flortaucipir F 18 safety and tau binding as measured by PET imaging and to provide standardized conditions for flortaucipir PET use, data collection and analysis to facilitate companion studies including, but not limited to, longitudinal studies of aging, depression, and traumatic brain injury.
Interventions
- DRUG Flortaucipir F18
- PROCEDURE Brain PET scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2014-12 |
| Est. Completion | 2019-06-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02278367
The ClinicalTrials.gov registry entry for NCT02278367 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Flortaucipir F18 is the first listed.
NCT02278367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02278367 about?
NCT02278367 is a clinical study titled "Clinical Evaluation of Flortaucipir F 18". This study is designed to expand the database of flortaucipir F 18 safety and tau binding as measured by PET imaging and to provide standardized conditions for flortaucipir PET use, data collection and analysis to facilitate companion studies including, but not limited to, longitudinal studies of ag...
What is the current status of trial NCT02278367?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2014-12. Estimated completion is 2019-06-26.
What interventions are being tested in trial NCT02278367?
The interventions under investigation include: Flortaucipir F18 (DRUG), Brain PET scan (PROCEDURE).
Who is sponsoring clinical trial NCT02278367?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.